GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (STU:L1PA) » Definitions » Piotroski F-Score

Lee's Pharmaceutical Holdings (STU:L1PA) Piotroski F-Score : 5 (As of Mar. 30, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Lee's Pharmaceutical Holdings Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Lee's Pharmaceutical Holdings has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Lee's Pharmaceutical Holdings's Piotroski F-Score or its related term are showing as below:

STU:L1PA' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 5
Current: 5

During the past 13 years, the highest Piotroski F-Score of Lee's Pharmaceutical Holdings was 5. The lowest was 2. And the median was 4.


Lee's Pharmaceutical Holdings Piotroski F-Score Historical Data

The historical data trend for Lee's Pharmaceutical Holdings's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lee's Pharmaceutical Holdings Piotroski F-Score Chart

Lee's Pharmaceutical Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 4.00 5.00 5.00 -

Lee's Pharmaceutical Holdings Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 - 5.00 - -

Competitive Comparison of Lee's Pharmaceutical Holdings's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Lee's Pharmaceutical Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lee's Pharmaceutical Holdings's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lee's Pharmaceutical Holdings's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Lee's Pharmaceutical Holdings's Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was €2.0 Mil.
Cash Flow from Operations was €12.9 Mil.
Revenue was €123.6 Mil.
Gross Profit was €64.7 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was (337.328 + 339.412) / 2 = €338.37 Mil.
Total Assets at the begining of this year (Dec22) was €337.3 Mil.
Long-Term Debt & Capital Lease Obligation was €8.8 Mil.
Total Current Assets was €77.1 Mil.
Total Current Liabilities was €76.2 Mil.
Net Income was €6.2 Mil.

Revenue was €149.5 Mil.
Gross Profit was €93.5 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was (412.701 + 337.328) / 2 = €375.0145 Mil.
Total Assets at the begining of last year (Dec21) was €412.7 Mil.
Long-Term Debt & Capital Lease Obligation was €9.7 Mil.
Total Current Assets was €79.0 Mil.
Total Current Liabilities was €78.8 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Lee's Pharmaceutical Holdings's current Net Income (TTM) was 2.0. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Lee's Pharmaceutical Holdings's current Cash Flow from Operations (TTM) was 12.9. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=1.961/337.328
=0.00581333

ROA (Last Year)=Net Income/Total Assets (Dec21)
=6.218/412.701
=0.0150666

Lee's Pharmaceutical Holdings's return on assets of this year was 0.00581333. Lee's Pharmaceutical Holdings's return on assets of last year was 0.0150666. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Lee's Pharmaceutical Holdings's current Net Income (TTM) was 2.0. Lee's Pharmaceutical Holdings's current Cash Flow from Operations (TTM) was 12.9. ==> 12.9 > 2.0 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=8.756/338.37
=0.025877

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=9.692/375.0145
=0.02584433

Lee's Pharmaceutical Holdings's gearing of this year was 0.025877. Lee's Pharmaceutical Holdings's gearing of last year was 0.02584433. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=77.099/76.182
=1.01203696

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=79.012/78.827
=1.00234691

Lee's Pharmaceutical Holdings's current ratio of this year was 1.01203696. Lee's Pharmaceutical Holdings's current ratio of last year was 1.00234691. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Lee's Pharmaceutical Holdings's number of shares in issue this year was 588.836. Lee's Pharmaceutical Holdings's number of shares in issue last year was 588.835. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=64.733/123.644
=0.5235434

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=93.456/149.522
=0.62503177

Lee's Pharmaceutical Holdings's gross margin of this year was 0.5235434. Lee's Pharmaceutical Holdings's gross margin of last year was 0.62503177. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=123.644/337.328
=0.36653939

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=149.522/412.701
=0.36230104

Lee's Pharmaceutical Holdings's asset turnover of this year was 0.36653939. Lee's Pharmaceutical Holdings's asset turnover of last year was 0.36230104. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+1+0+0+1
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Lee's Pharmaceutical Holdings has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Lee's Pharmaceutical Holdings  (STU:L1PA) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Lee's Pharmaceutical Holdings Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Lee's Pharmaceutical Holdings Business Description

Traded in Other Exchanges
Address
Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.

Lee's Pharmaceutical Holdings Headlines

No Headlines